**Table S1:** Overview of the RFS rates for all patients and group analyses

|  |  |  |
| --- | --- | --- |
| **Patient Groups (number of transplants/patients)** | **Relapse-Free Survival (%)** | ***P*-value****(log-rank test)** |
|  | One-year | Two-year | Three-year |  |
| All transplanted patients (80) | 47.5 | 40.7 | 37.3 |  |
| MUD (49)MRD (21)MMUD (10) | 46.952.440.0 | 38.047.140.0 | 35.439.340.0 | 0.76 |
| CR (37)Non-CR (43) | 48.646.5 | 37.541.5 | 34.138.0 | 0.907 |
| <50 years (27)≥50 years (53) | 44.449.1 | 37.043.1 | 33.340.2 | 0.969 |
| AML patients (58) | 43.3 | 38.1 | 33.5 |  |

AML, acute myeloid leukemia; CR, complete remission; MMUD, mismatched unrelated donor; MRD, matched-related donor; MUD, matched-unrelated donor.

**Table S2:** Overview of the OS rates for all patients and group analyses

|  |  |  |
| --- | --- | --- |
| **Patient Groups (number of transplanted patients)** | **Overall Survival (%)** | ***P*-value****(log-rank test)** |
|  | One-year | Two-year | Three-year |  |
| All patients (77) | 59.3 | 49.3 | 45.4 |  |
| MUD (48)MRD (20)MMUD (9) | 56.870.048.0 | 49.948.148.0 | 46.740.148.0 | 0.95 |
| CR (35)Non-CR (42)  | 65.654.3 | 53.346.2 | 45.146.2 | 0.996 |
| <50 years (25)≥50 years (52) | 58.160.3 | 54.247.4 | 44.444.5 | 0.785 |
| AML patients only (58) | 56.5 | 48.9 | 43.5 |  |

AML, acute myeloid leukemia; CR, complete remission; MMUD, mismatched unrelated donor; MRD, matched-related donor; MUD, matched-unrelated donor.